We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Revolutionary Blood Test to Transform Early Diagnosis of Bowel Cancer

By LabMedica International staff writers
Posted on 20 May 2022

Bowel (colorectal) cancer is the second most common cancer globally. More...

It is the leading cause of cancer-related death in the Western world. Early diagnosis of bowel cancer significantly reduces mortality rate. Current diagnostics tests such as colonoscopy or fecal blood detection kits can be invasive, unpleasant and expensive. Now, an accurate, non-invasive, inexpensive blood test can diagnose bowel cancer early and dramatically cut waiting times for diagnosis while reducing the need for unnecessary invasive procedures such as colonoscopies.

Researchers at Swansea University (Swansea, UK) have devised a simple Raman Spectrometry (RS) blood test which can return test results in under 20 minutes. Using innovations based around laser spectroscopy and artificial intelligence (AI) -based analytics, the test analyses cancer-driven metabolic activity in blood that their AI software is trained to interpret and diagnose. The test aims to break down patient anxiety with a highly accurate test to give rapid reassurance to those who have not got cancer and ensure they do not need an invasive colonoscopy. As a result, this will free up valuable endoscopy and colonoscopy resource and speed up treatment for those who have cancer while resulting in savings from a reduction of needless colonoscopies.

Results from a ground-breaking study involving 27 practices and 595 patients showed 79% of early-stage bowel cancers and 100% of advanced bowel cancers were picked up by the test. Early comparisons with other tests currently available in primary care have shown the RS blood test to have greater sensitivity for the detection of bowel cancer. Currently, a high number of unnecessary colonoscopies are conducted to ensure cases of bowel cancer are detected. Since the start of the pandemic, waiting lists for the procedure have significantly increased. These delays can reduce the chances of patient survival, with many people being diagnosed too late. The blood test hopes to change all that by providing accurate results within 48 hours, preventing unnecessary colonoscopies and relieving pressure on healthcare systems.

Related Links:
Swansea University 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Silver Member
Vitamin D Assay
EZ Vitamin D Assay
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.